Rong Wang, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is a cancer epidemiologist who studies the health outcomes and etiology of different types of cancers, especially hematopoietic malignancies. She is interested in the pattern of care, treatment and cost in older adults. She is also working on traffic exposure and genetic characteristics on the risk of cancer.
Last Updated on May 09, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Yale University (2008)
Research
Copy Link
Overview
Medical Research Interests
Biostatistics; Chronic Disease; Epidemiology; Health Care; Neoplasms
Public Health Interests
Maternal & Child Health; Environmental Health; Cancer
ORCID
0000-0002-2169-4174
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rong Wang's published research.
Publications Timeline
A big-picture view of Rong Wang's research output by year.
Research Interests
Research topics Rong Wang is interested in exploring.
Xiaomei Ma, PhD
Nikolai Podoltsev, MD, PhD
Scott Huntington, MD, MPH, MSc
Amer Zeidan, MBBS, MD
Natalia Neparidze, MD
Jan Philipp Bewersdorf, MD, FACP
121Publications
6,573Citations
Neoplasms
Chronic Disease
Publications
2026
Overestimation of multiple myeloma survival from cancer registry data
Huber J, Wang M, Wang R, Schoen M, Colditz G, Wang S, Chang S. Overestimation of multiple myeloma survival from cancer registry data. Journal Of The National Cancer Institute 2026, djag028. PMID: 41652897, PMCID: PMC12967285, DOI: 10.1093/jnci/djag028.Peer-Reviewed Original ResearchAltmetricConceptsSymptomatic MMMultiple myelomaFive-year relative survival estimatesSurvival statisticsCancer registry dataRelative survival estimatesMM managementPremalignant conditionSurveillance, EpidemiologyMultiple myeloma survivalRegistry dataMedian survivalMM survivalMyeloma survivalSEERPopulation levelSurvival estimatesSurvivalMyelomaMonthsStatisticallyInclusionEpidemiologyPatientsSmoldering multiple myeloma in the United States: a population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricResidential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California
Clark C, Johnson N, Wang R, Stewart E, Spector L, Wiemels J, Metayer C, Deziel N, Ma X. Residential proximity to active and abandoned oil and gas development and risk of childhood Ewing sarcoma in California. Environmental Health 2026, 25: 12. PMID: 41535920, PMCID: PMC12888232, DOI: 10.1186/s12940-025-01259-3.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSarcoma riskControls frequency-matched to casesHispanic childrenFrequency-matched to casesOdds ratioCalifornia Cancer RegistryClustering of cancerConfidence intervalsPediatric cancer riskNon-Hispanic childrenMultivariate logistic regressionBirth addressCancer RegistryHealth outcomesEwing sarcomaNon-HispanicCancer riskChildhood cancerResidential proximityBirth yearUnexposed childrenLogistic regressionMethodsThis studyExposure disparitiesDiagnosis of Ewing's sarcomaTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang R, Davidoff A, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Chang S, Wang S. Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022. American Journal Of Hematology 2026, 101: 923-925. PMID: 41528052, PMCID: PMC12912868, DOI: 10.1002/ajh.70202.Commentaries, Editorials and LettersAltmetric
2025
Evaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000–2022)
Ning X, Wang R, Ogilvie J, Dinauer C, Ma X, Deziel N. Evaluation of disparities in the incidence, presentation, and treatment of pediatric differentiated thyroid cancer in the United States (2000–2022). PLOS ONE 2025, 20: e0333401. PMID: 41100458, PMCID: PMC12530529, DOI: 10.1371/journal.pone.0333401.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNon-Hispanic Asian/Pacific IslanderNon-Hispanic white patientsAnnual percent changeAsian/Pacific IslanderSocioeconomic statusNational childhood cancer registryChildhood Cancer RegistryWhite patientsJoinpoint regression analysisNon-Hispanic blacksPediatric thyroid cancer incidenceThyroid cancer incidenceCancer management guidelinesManagement guidelinesEvaluation of disparitiesNon-white childrenThyroid cancer management guidelinesCancer RegistryCancer incidenceTumor sizeThyroid cancerCancer presentationHispanic childrenTimely accessPercent changeChanges in Colorectal Cancer Screening Modalities Among Insured Individuals
Siddique S, Wang R, May F, Baum L, Gross C, Ma X. Changes in Colorectal Cancer Screening Modalities Among Insured Individuals. JAMA Network Open 2025, 8: e2538578. PMID: 41118161, PMCID: PMC12541536, DOI: 10.1001/jamanetworkopen.2025.38578.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFecal immunochemical testStool DNA testColorectal cancer screening modalitiesSocioeconomic statusScreening modalitiesMetropolitan area residentsRetrospective cohort studyDynamic cohortArea-level socioeconomic statusColorectal cancerMarkers of socioeconomic statusCohort studyTest useArea residentsAverage-risk individualsCancer screening modalitiesDNA testingImmunochemical testCOVID-19 pandemicSociodemographic groupsMain OutcomesClaims dataColonoscopyCOVID-19ResidentsGastric Adenocarcinoma in the United States: The Toll of Late Diagnosis and Racial and Geographic Disparities
Hyun C, Wang R, Kim Y, Hong S, Shin J, Sundar R, Kunz P. Gastric Adenocarcinoma in the United States: The Toll of Late Diagnosis and Racial and Geographic Disparities. JCO Oncology Advances 2025 DOI: 10.1200/oa-25-00063.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGastric adenocarcinomaPoor survivalHazard ratioGastric cancerMedian survivalGeographic disparitiesRacial disparitiesDistant stageNon-Hispanic black patientsSurvival rateNon-Hispanic AsiansTargeted prevention strategiesEarly detection effortsHigh-risk populationTumor locationSurvival outcomesLate diagnosisPrevention strategiesElevated riskUnited StatesBlack patientsDetection programGA incidenceGA casesDisparitiesSecond malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib
Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.Peer-Reviewed Original ResearchAltmetricConceptsSecond malignanciesMyeloproliferative neoplasmsOlder patientsEssential thrombocythemiaPolycythemia veraPhiladelphia chromosome-negative myeloproliferative neoplasmsDevelopment of second malignanciesRisk of non-melanoma skin cancerEnd Results Medicare-linked databaseNon-melanoma skin cancerMedian Follow-UpMedicare-linked databaseTherapy-related effectsRetrospective cohort analysisRisk of SMHazards regression modelsProportion of daysRuxolitinib exposureMedian ageFollow-upRuxolitinibCohort analysisSkin cancerPatientsMyelofibrosisArea-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries
Smani S, Wang R, Zhou X, Sprenkle P, Kim I, Dinan M, Gross C, Ma X, Leapman M. Area-Level Social Deprivation and Use of Prostate MRI Before Prostate Biopsy Among Commercial Insurance Beneficiaries. Urology 2025, 205: 145-151. PMID: 40759400, DOI: 10.1016/j.urology.2025.07.070.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPre-biopsy magnetic resonance imagingProstate magnetic resonance imagingMagnetic resonance imagingMagnetic resonance imaging useProstate biopsySocial deprivation indexArea-level measuresDynamic cohort studyMRI useMeasure of area-level deprivationSocioeconomic statusArea-level social deprivationArea-level measures of socioeconomic statusMeasures of socioeconomic statusStrata of socioeconomic statusArea-level deprivationCommercial insurance beneficiariesComposite measureBiopsyProstateNon-metropolitan areasDeprivation indexRural/urban statusResonance imagingSociodemographic factorsCalcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Calcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database. Therapeutic Advances In Hematology 2025, 16: 20406207251394775. PMID: 41333634, PMCID: PMC12665816, DOI: 10.1177/20406207251394775.Peer-Reviewed Original ResearchConceptsAcquired Aplastic AnemiaCalcineurin inhibitorsTransfusion requirementsTransfusion burdenDouble therapySevere AATriple therapyAplastic anemiaCombination therapyAllogeneic hematopoietic stem cell transplantationEquine anti-thymocyte globulinEffects of calcineurin inhibitorsRare bone marrow failure syndromeHematopoietic stem cell transplantationBone marrow failure syndromesFirst-line treatment optionAnti-thymocyte globulinStem cell transplantationMarrow failure syndromesTreatment-related complicationsImmune-mediated destructionRisk of bleedingRetrospective cohort studyAdherence to treatmentTransfusion-independent
News
Copy Link
News
- October 28, 2025Source: Yale News
Study Reveals Demographic Disparities in Uptake of Colorectal Cancer Screenings
- October 27, 2025
New Study Highlights Need for Coordinated Approach to Stomach Cancer Screening and Prevention
- June 03, 2025Source: Yale News
Insights & Outcomes: Star Music, Kavli Kudos, and Summertime Heart Risks
- May 14, 2025
Faculty Research Awards Showcase YSPH Strengths in Science
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
1 Church Street
Academic Office
Ste 200, Rm 225
New Haven, CT 06510